BridgeBio Pharma, Inc. (BBIO) Spending and interest coverage
- R&D / revenue · 12 months: Value 70.87%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 20.65%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 70.87% | Research and development expense / revenue. Period ending 2026-06-30. $505.38M ÷ $713.07M × 100 ≈ 70.87% |
| Stock-based compensation / revenue · 12 months | 20.65% | Share-based compensation / revenue. Period ending 2026-06-30. $147.22M ÷ $713.07M × 100 ≈ 20.65% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 505.38M USD | Research and Development Expense |
| Revenue | 713.07M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 147.22M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -497.80M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $505.38M | $713.07M | $147.22M | $-497.80M | (m) | 70.87% | 20.65% | (m) | (m) |
| 2026-03-31 | $467.16M | $579.96M | $140.38M | $-525.00M | (m) | 80.55% | 24.21% | (m) | (m) |
| 2025-12-31 | $451.95M | $502.08M | $133.02M | $-523.41M | (m) | 90.02% | 26.49% | (m) | (m) |
| 2025-09-30 | $465.89M | $353.78M | $128.51M | $-609.88M | (m) | 131.69% | 36.33% | (m) | (m) |
| 2025-06-30 | $473.46M | $235.81M | $120.41M | $-656.43M | (m) | 200.78% | 51.06% | (m) | (m) |
| 2025-03-31 | $476.92M | $127.42M | $104.63M | $-697.69M | (m) | 374.30% | 82.11% | (m) | (m) |
| 2024-12-31 | $506.46M | $221.90M | $95.80M | $-592.97M | (m) | 228.24% | 43.17% | (m) | (m) |
| 2024-09-30 | $506.34M | $217.76M | $102.70M | $-544.36M | (m) | 232.52% | 47.16% | (m) | (m) |
| 2024-06-30 | $511.03M | $219.12M | $98.14M | $-510.30M | $86.98M | 233.21% | 44.79% | -5.87× | Reported |
| 2024-03-31 | $503.82M | $218.60M | $103.86M | $-480.86M | $84.64M | 230.48% | 47.51% | -5.68× | Reported |
| 2023-12-31 | $455.71M | $9.30M | $108.71M | $-607.37M | $81.29M | 4898.54% | 1168.55% | -7.47× | Reported |
| 2023-09-30 | $416.39M | $9.43M | $93.47M | $-559.19M | $81.01M | 4416.49% | 991.45% | -6.90× | Reported |
| 2023-06-30 | $383.76M | $5.67M | $88.23M | $-530.61M | $80.53M | 6762.33% | 1554.80% | -6.59× | Reported |
| 2023-03-31 | $384.67M | $77.78M | $89.34M | $-464.69M | $80.22M | 494.57% | 114.87% | -5.79× | Reported |
| 2022-12-31 | $399.46M | $77.65M | $91.56M | $-512.20M | $80.44M | 514.45% | 117.92% | -6.37× | Reported |
| 2022-09-30 | $430.76M | $88.66M | $89.54M | $-548.58M | $75.58M | 485.83% | 100.99% | -7.26× | Reported |
| 2022-06-30 | $442.55M | $90.67M | $88.22M | $-568.97M | $66.82M | 488.09% | 97.30% | -8.51× | Reported |
| 2022-03-31 | $436.11M | $70.95M | $90.05M | $-582.81M | $57.38M | 614.70% | 126.92% | -10.16× | Reported |
| 2021-12-31 | $451.02M | $69.72M | $99.50M | $-576.63M | $46.78M | 646.94% | 142.73% | -12.33× | Reported |
| 2021-09-30 | $419.00M | $56.95M | $91.88M | $-538.51M | $42.61M | 735.70% | 161.32% | -12.64× | Reported |
| 2021-06-30 | $406.74M | $62.73M | $93.53M | $-508.95M | $42.47M | 648.35% | 149.09% | -11.98× | Reported |
| 2021-03-31 | $391.38M | (m) | $81.81M | $-539.50M | $42.38M | (m) | (m) | -12.73× | Reported |
| 2020-12-31 | $337.05M | $8.25M | $58.46M | $-474.48M | $36.66M | 4085.91% | 708.68% | -12.94× | Reported |
| 2020-09-30 | $304.36M | $21.95M | $56.32M | $-425.63M | $28.73M | 1386.85% | 256.63% | -14.81× | Reported |
| 2020-06-30 | $267.59M | (m) | $44.40M | $-360.22M | $19.92M | (m) | (m) | -18.09× | Reported |
| 2020-03-31 | $233.32M | (m) | $29.36M | $-304.98M | $11.10M | (m) | (m) | -27.47× | Reported |
| 2019-12-31 | $209.95M | $40.56M | $21.37M | $-266.24M | $8.77M | 517.62% | 52.70% | -30.38× | Reported |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $140.07M | (m) | $6.07M | $-183.66M | $2.55M | (m) | (m) | -72.11× | Reported |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $30.56M | (m) | $1.84M | $-43.86M | $13.00K | (m) | (m) | -3373.69× | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |